Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S373000, C548S161000, C548S168000, C548S178000, C548S207000, C548S212000
Reexamination Certificate
active
07041691
ABSTRACT:
Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
REFERENCES:
patent: 2407309 (1946-09-01), Lott et al.
patent: 3034955 (1962-05-01), Frick et al.
patent: 3674843 (1972-07-01), Shen et al.
patent: 3686192 (1972-08-01), Moore et al.
patent: 4003734 (1977-01-01), Johnston
patent: 4013621 (1977-03-01), Knell
patent: 4061642 (1977-12-01), Fleckenstein et al.
patent: 4218237 (1980-08-01), Nishiyama et al.
patent: 4289876 (1981-09-01), Algieri et al.
patent: 4499304 (1985-02-01), Gabrielsen et al.
patent: 4549901 (1985-10-01), James
patent: 4565568 (1986-01-01), Johnston et al.
patent: 4577028 (1986-03-01), Martin et al.
patent: 4670045 (1987-06-01), Ehr et al.
patent: 4731090 (1988-03-01), Boger et al.
patent: 4756739 (1988-07-01), Fuss et al.
patent: 4851419 (1989-07-01), Cox
patent: 4866079 (1989-09-01), Boger et al.
patent: 4900751 (1990-02-01), Cox
patent: 4946854 (1990-08-01), Maienfisch et al.
patent: 4952235 (1990-08-01), Andree et al.
patent: 4987141 (1991-01-01), Bushell et al.
patent: 5008276 (1991-04-01), Clough et al.
patent: 5070096 (1991-12-01), Mohrs et al.
patent: 5093340 (1992-03-01), Mohrs et al.
patent: 5143937 (1992-09-01), Lang et al.
patent: 5151428 (1992-09-01), Sakamoto et al.
patent: 5202336 (1993-04-01), Mohrs et al.
patent: 5204354 (1993-04-01), Chakravarty et al.
patent: 5250549 (1993-10-01), Yoshino et al.
patent: 5304532 (1994-04-01), Munro et al.
patent: 5360810 (1994-11-01), Hayase et al.
patent: 5444036 (1995-08-01), Iwasaki et al.
patent: 5514696 (1996-05-01), Murugesan et al.
patent: 5545669 (1996-08-01), Adams et al.
patent: 5610320 (1997-03-01), Yoshino et al.
patent: 5624937 (1997-04-01), Reel
patent: 5643914 (1997-07-01), Daines
patent: 5684195 (1997-11-01), Huang et al.
patent: 5716993 (1998-02-01), Ozaki et al.
patent: 5780483 (1998-07-01), Widdowson et al.
patent: 5814646 (1998-09-01), Heinz
patent: 5880136 (1999-03-01), Duggan et al.
patent: 5990126 (1999-11-01), Park et al.
patent: 6028052 (2000-02-01), Heyman et al.
patent: 6200995 (2001-03-01), De la Brouse-Elwood et al.
patent: 6262112 (2001-07-01), Mittendorf et al.
patent: 6294559 (2001-09-01), Smith
patent: 6348474 (2002-02-01), Kayakiri et al.
patent: 6353011 (2002-03-01), Pershadsingh et al.
patent: 6369075 (2002-04-01), Ruggeri et al.
patent: 6469054 (2002-10-01), Mittendorf et al.
patent: 6545050 (2003-04-01), Mittendorf et al.
patent: 6583157 (2003-06-01), McGee et al.
patent: 6586475 (2003-07-01), Kato et al.
patent: 6653309 (2003-11-01), Saunders et al.
patent: 2003/0088103 (2003-05-01), Houze et al.
patent: 2004/0048891 (2004-03-01), Kato et al.
patent: 592 411 (1977-10-01), None
patent: 3632329 (1988-03-01), None
patent: 3632329 (1988-03-01), None
patent: 069 585 (1983-01-01), None
patent: 0 148 730 (1985-07-01), None
patent: 0 261 539 (1988-03-01), None
patent: 0 306 222 (1989-03-01), None
patent: 0 749 751 (1996-06-01), None
patent: 0778 267 (1996-11-01), None
patent: 0 855 391 (1997-08-01), None
patent: 0 472 053 (1998-06-01), None
patent: 55-79369 (1980-06-01), None
patent: 64-6245 (1989-01-01), None
patent: 9-255656 (1997-09-01), None
patent: WO 99/38845 (1965-02-01), None
patent: WO 95/01326 (1995-01-01), None
patent: WO95/01326 (1995-01-01), None
patent: WO 95/33461 (1995-12-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/15118 (1996-05-01), None
patent: WO 97/30677 (1997-08-01), None
patent: WO97/00857 (1997-09-01), None
patent: WO 97/31907 (1997-09-01), None
patent: WO 97/36579 (1997-10-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/27081 (1998-06-01), None
patent: WO 98/50029 (1998-11-01), None
patent: WO 98/50030 (1998-11-01), None
patent: WO 99/06378 (1999-02-01), None
patent: WO 99/10320 (1999-03-01), None
patent: WO 99/50237 (1999-10-01), None
patent: WO 99/55663 (1999-11-01), None
patent: WO 00/12073 (2000-03-01), None
patent: WO 00/12623 (2000-03-01), None
patent: WO 00/17202 (2000-03-01), None
patent: WO 01/00579 (2001-01-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 01/70723 (2001-09-01), None
patent: WO 01/83427 (2001-11-01), None
patent: WO 01/87861 (2001-11-01), None
patent: WO 01/87862 (2001-11-01), None
patent: WO 01/95906 (2001-12-01), None
patent: WO 01/87860 (2002-11-01), None
Lehmann et al., “Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs,”The Journal of Biological Chemistry, (1997) 272(6):3406-3410.
Wilson et al., “The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones,”J. Med. Chem.,(1996) 39:665-668.
Forman et al., “15-Deoxy-Δ12, 14-Prostaglandin J2Is a Ligand for the Adipocyte Determination Factor PPARγ,”Cell,(1995) 83:803-812.
Burmistrov et al., Database accession No. 122:132338, Database Chemabs 'Online!, RN 134284-40-5 CAPLUS,Zh. Org. Khim,(1994) 30(5):744-747.
Sebe et al., Database accession No. 117:214517, Database Chemabs 'Online!, RNs 144206-02-0 CAPLUS, 144232-65-5 CAPLUS,Rev. Chim,(1992),43(5-6):222-225.
Burmistrov et al., Database accession No. 115:8165, Database Chemabs 'Online!, RNs 98187-76-9 CAPLUS, 134284-40-5 CAPLUS,Zh. Org. Khim,(1990) 26(9):1995-1998.
Pieper et al., Database accession No. 112:138679, Database Chemabs 'Online!, RN 101513-48-8 CAPLUS,Arzneim.-Forsch.,(1989) 39(9):1073-1080.
Baguley et al., Database accession No. 108:179602, Database Chemabs 'Online!, RN 106831-10-1 CAPLUS,Eur. J. Cancer Clin. Oncol.,(1988) 24(2):205-210.
Sarul, et al., Database accession No. 103:123106, Database Chemabs 'Online!, RN 98187-77-0 CAPLUS,Latv. Psr Zinat. Akad. Vestis, Kim. Ser.,(1985) 2:225-228.
Wollweber et al., Database accession No. 101:151540, Database Chemabs 'Online!, RN 92114-63-1 CAPLUS ,Arzneim.-Forsch.,(1984) 34(5):531-542.
Denny et al., Database accession No. 96:79437, Database Chemabs 'Online!, RNs 80260-24-8 CAPLUS, 80260-26-0 CAPLUS,J. Med. Chem.,(1982) 25(3):276-315.
Mysyk et al., Database accession No. 92:163637, Database Chemabs 'Online!, RN 73320-75-9 CAPLUS,Zh. Org. Khim,(1979) 15(12):2499-2502.
Zaitseva et al., Database accession No. 86:43377, Database Chemabs 'Online!, RN 61381-98-4 CAPLUS,Zh. Org. Khim,(1976) 12(9):1987-1992.
Lehmann, J., et al., “An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)★,”J. Bio. Chem.270(22): 12953-12956 (1995).
Chemical Abstracts, vol. 67, No. 9, Aug. 28, 1967, Columbus, Ohio, United States; abstract No. 43516y, p. 4076; XP002099084; & I. Badilescu: “Sythesis of some N-aryl- and N,N-dialkyl-p-chloro-benzensulfonamides” REV.CHIM., vol. 17, No. 11, 1966 pp. 705-706.
U.S. Appl. No. 09/847,887, filed May 2001, Jaen et al.
U.S. Appl. No. 09/741,415, filed Dec. 2000, de la Brousse-Elwood et al.
U.S. Appl. No. 10/278,851, McGee et al.
U.S. Appl. No. 10/456,932, Jaen et al.
Cain et al., “Potential antitumor agents. 14. Acridylmethanesulfonanilides,”J. Med. Chem.17(9):922-930 (1974).
Chaturvedi et al., “Antibacterial studies of 7-(α-substituted sulfonamido)methyl- and 7-(α-substituted sulfonamido)phenyl-8-hydroxyquinolines,”Journal of the Indian Chemical Society61(2):175-176 (1984) (Abstract. Chem. Abstract Accession No.: 101:87311).
Collins et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety,”J. Med. Chem.41(25):5037-5054 (1998).
Dumas et al., “Synthesis and structure-activity relationships of novel small molecule cathepsin D Inhibitors,”Bioorg. Med. Chem. Lett.9(17):2531-2536 (1999) (Abstract. Chem. Abstract Accession No.: 131:336969).
Jiang et al., “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,”Nature391:82-86 (1998).
Ricote et al., “The pe
Houze Jonathan B.
McGee Lawrence R.
Rubenstein Steven M.
Amgen Inc.
Seaman D. Margaret
Townsend and Townsend / and Crew LLP
LandOfFree
Compounds for the modulation of PPARγ activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the modulation of PPARγ activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the modulation of PPARγ activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3547604